Breast Cancer Treatment Journal

The American Joint Committee on Cancer's Cancer Staging Manual is used by physicians throughout the world to diagnose cancer and determine the extent to which cancer has progressed. All of the TNM staging information included in this Sixth Edition is uniform between the AJCC (American Joint Committee on Cancer) and the UICC (International Union Against Cancer). In addition to the information found in the Handbook, the Manual provides standardized data forms for each anatomic site, which can be utilized as permanent patient records, enabling clinicians and cancer research scientists to maintain consistency in evaluating the efficacy of diagnosis and treatment. The CD-ROM packaged with each Manual contains printable copies of each of the book’s 45 Staging Forms.

This book is a comprehensive guide to breast toxicity. Adjuvant radiation remains standard for a majority of women who undergo breast-conserving surgery for breast cancer, and indications for post-mastectomy and regional lymph node irradiation have also broadened with recent publications. At the same time, locoregional recurrence has declined and survival has improved in recent decades. In the current era of excellent breast cancer outcomes, then, considering the balance between toxicity and outcomes becomes paramount. Several recent editorials recommend considering toxicity against the potential benefit of adjuvant radiation in tailoring radiation decisions for individual patients. Thus, a clear understanding of the potential toxicities of adjuvant radiation for breast cancer is critical to optimizing outcomes in modern breast cancer management. Here, authors have collected recent data focused on toxicity of treatment that provide an opportunity for improving this optimization. Chapters cover both acute and late toxicity of radiation for breast cancer, including tailored risk assessment for each of these potential toxicities, considerations for including risk of toxicity in management decisions, and toxicity management strategies. This is an ideal guide for radiation oncologists, residents, and oncologists seeking to optimize care for their patients.

Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.

A diagnosis of breast cancer can be overwhelming. The disease is frightening and the medical landscape confusing. In the wake of fear and confusion comes the need to make decisions about treatment. This book provides women with medically reliable and up-to-date information to help them with these decisions. Within these pages is a team of private consultants—including surgeons, medical oncologists, radiologists, plastic surgeons, and women who have faced breast cancer—each of whom offers sound advice and valuable insight. In addition to describing surgery, radiation, chemotherapy, hormone therapy, and breast reconstruction, the medical experts clarify choices and offer support, while breast cancer survivors tell their own stories of pain, perseverance, and triumph. Choices in Breast Cancer Treatment is a rare blend of medical expertise and compelling personal accounts that empowers those with breast cancer to meet the disease with confidence, knowledge, and hope.

During the past twenty years tamoxifen has become the most widely prescribed and most successful drug used in the treatment of breast cancer. In this volume, editor V. Craig Jordan provides articles that trace the development, pharmacology, and clinical research surrounding this drug which, by the year 2000, could be used to treat as many as one million women annually. Drawing from research conducted by specialists in the United States, the United Kingdom, and Italy, the series of articles describes the clinical testing of tamoxifen, highlighting the benefits. Studies show that tamoxifen lowers cholesterol and can potentially protect women against osteoporosis and fatal coronary heart disease. Equally important is a discussion of side effects and possible drug interactions and how these issues relate to patient concerns. An investigation of the development of a new class of drugs for use after tamoxifen fails provides valuable insight into future treatments, as the contributers consider possible resistance to tamoxifen. This volume provides invaluable information for physicians and surgeons who care for patients with breast cancer and for women interested in exploring this therapeutic dimension.

This book is a compilation and discussion of data on the survival of cancer patients in 12 European countries. Measures of incidence, survival and mortality are critical to the interpretation of data on progress in the fight against cancer, and in the evaluation of the overall effectiveness of cancer control programmes. Randomized controlled clinical trials have shown many modern protocols for cancer treatment to be more effective than earlier treatments, but until now, comparable population-based survival figures have raraly been available. EUROCARE is a concerted action among European cancer registries, aimed at estimating and comparing the survival of cancer patients in different European populations. The rationale behind this project is to optimize the comparability of survival data by using an agreed and standard definition of the diseases for which survival is to be compared, and by taking due account of basic demographic variables. The EUROCARE Working Group succeeded in collecting, checking and editing data on cancer survival from 30 cancer registries in 12 countries, and established a database covering some 800,000 cancer patients in the period 1978-85 and followed up to the end of 1990. This database forms the raw material for this monograph.

Breast cancer is the most common cancer in females that accounts for highest cancer specific deaths worldwide. In the last few decades research has proven that breast cancer can be treated if diagnosed at early stages and proper therapeutic strategy is adopted. Omics-based recent approaches have unveiled the molecular mechanism behind the breast tumorigenesis and aid in identification of next-generation molecular markers for early diagnosis, prognosis and even the effective targeted therapy. Significant development has taken place in the field of omics in breast cancer in the last decade. The most promising omics approaches and their outcomes in breast cancer have been presented in this book for the first time. The book covers omics technologies and budding fields such as breast cancer miRNA, lipidomics, epigenomics, proteomics, nutrigenomics, stem cell, pharmacogenomics and personalized medicine and many more along with conventional topics such as breast cancer management etc. It is a research-based reference book useful for clinician-scientists, researchers, geneticists and health care industries involved in various aspects of breast cancer. The book will also be useful for students of biomedicine, pathology and pharmacy.

This book describes recent advances in translational research in breast cancer and presents emerging applications of this research that promise to have meaningful impacts on diagnosis and treatment. It introduces ideas and materials derived from the clinic that have been brought to "the bench" for basic research, as well as findings that have been applied back to "the bedside". Detailed attention is devoted to breast cancer biology and cell signaling pathways and to cancer stem cell and tumor heterogeneity in breast cancer. Various patient-derived research models are discussed, and a further focus is the role of biomarkers in precision medicine for breast cancer patients. Next-generation clinical research receives detailed attention, addressing the increasingly important role of big data in breast cancer research and a wide range of other emerging developments. An entire section is also devoted to the management of women with high-risk breast cancer. Translational Research in Breast Cancer will help clinicians and scientists to optimize their collaboration in order to achieve the common goal of conquering breast cancer.